Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Clarkson shares tank as US tariff war sparks profit warning

(Sharecast News) - Shares in ship broker Clarkson slumped on Thursday after the company issued a profit warning, citing the impact of US tariffs and weaker US dollar. The shipping services company said underlying pre-tax earnings would now be £85m - £95m. Clarkson shares tanked in March after it warned the US President Donald Trump's trade tariffs, political tensions and economic weakness had resulted in lower freight rates and asset values.

At the time it had also unveiled record profits of £115.3m. Shares in the company fell 10.6% in London

In a trading update ahead of its annual general shareholder meeting, Clarkson said shipping rates were running 7% lower in dollar terms than anticipated at the time of the full year results on March 10.

It warned that if US dollar exchange rates remained at current levels to the end of 2025 "profits would be reduced by £9.5m" compared with previous expectations.

"Whilst the board believes that the effect of current macro uncertainty has the potential to be reversed once normality returns to the markets, it now expects that the recent changes in US government policy will impact results for 2025," the company said.

Trump's erratic trade policies have caused market volatility across the globe. Most imports to the US face a 10% tariff but those from China have been hit with a 145% levy while Beijing has has retaliated by imposing a 125% duty on US imports.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.